Loading...

PE anti-mouse CD86 Antibody PE anti-mouse CD86 Antibody

Pricing & Availability
Clone
GL-1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-2, B70, Ly-58
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
GL-1
LPS (3-day) stimulated BALB/c mouse splenocytes stained with GL-1 PE
  • GL-1
    LPS (3-day) stimulated BALB/c mouse splenocytes stained with GL-1 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
105008 200 µg NOK2418
Check Availability


Need larger quantities of this item?
Request Bulk Quote
105007 50 µg NOK908
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
LPS-activated CBA/Ca mouse splenic B cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of acetone-fixed frozen sections2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105051-105056).

Application References
  1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
  2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
  5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
  6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
  11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed
Product Citations
  1. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  2. Liu C, et al. 2022. Regen Ther. 21:192. PubMed
  3. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  4. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  5. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  6. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  7. Pan L, et al. 2022. Mol Immunol. 147:101. PubMed
  8. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  9. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  10. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  11. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  12. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  13. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  14. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  15. Ye Z, et al. 2023. Front Med (Lausanne). 9:1075465. PubMed
  16. Grenov A, et al. 2022. Cell Rep. 39:110778. PubMed
  17. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  18. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  19. Li T, et al. 2023. Adv Sci (Weinh). 10:e2206517. PubMed
  20. Sheng Y, et al. 2023. Cancers (Basel). 15:. PubMed
  21. Solier S, et al. 2023. Nature. 617:386. PubMed
  22. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  23. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  24. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  25. Kitagawa S, et al. 2022. NPJ Vaccines. 7:115. PubMed
  26. El-Hindi K, et al. 2022. Int J Mol Sci. 23:. PubMed
  27. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  28. Moreau J, et al. 2015. Blood. 126: 1184-1192. PubMed
  29. Lauterbach MA, et al. 2020. Immunity. 51(6):997-1011.e7.. PubMed
  30. Zhang Y, et al. 2018. Sci Rep. 8:5994. PubMed
  31. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  32. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  33. Saito S, et al. 2020. Nutrients. 12:. PubMed
  34. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  35. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  36. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  37. Xie Y, et al. 2020. Journal of Neurochemistry. 152(3):368-380.. PubMed
  38. Song M, et al. 2021. J Immunol Res. 6696606:2021. PubMed
  39. Chen F, et al. 2022. Evid Based Complement Alternat Med. 2022:1240242. PubMed
  40. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  41. Wu Q, et al. 2022. Cell Mol Life Sci. 79:137. PubMed
  42. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  43. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  44. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  45. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  46. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  47. Wang S, et al. 2018. Biomaterials. 187:28:00. PubMed
  48. Škrnjug I, et al. 2014. PLoS One. 9:110150. PubMed
  49. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  50. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  51. Jin R, et al. 2020. Mol Cancer Ther. . PubMed
  52. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  53. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  54. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  55. Varol D et al. 2017. Immunity. 46(6):1030-1044 . PubMed
  56. Bell CC, et al. 2019. Nat Commun. 10:2723. PubMed
  57. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  58. Reddi RN, et al. 2021. J Am Chem Soc. 143:4979. PubMed
  59. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  60. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  61. Jiang W, et al. 2021. J Cell Physiol. 236:7711. PubMed
  62. Wang Y, et al. 2022. Cell Death Dis. 13:748. PubMed
  63. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  64. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  65. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  66. Kramer K, et al. 2017. ACS Omega. 0.240972222. PubMed
  67. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  68. Venter C, et al. 2021. Physiol Rep. 9:e14704. PubMed
  69. Fan Q, et al. 2021. Bioact Mater. 6:4014. PubMed
  70. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  71. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  72. Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed
  73. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  74. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  75. Guo D, et al. 2022. Bone Res. 10:45. PubMed
  76. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  77. Shih F, et al. 2006. J Immunol. 176:3438. PubMed
  78. Gupta P, et al. 2019. Neoplasia. 0.976388889. PubMed
  79. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  80. Grabinger T, et al. 2019. Front Microbiol. 10:1385. PubMed
  81. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  82. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  83. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  84. Tomimatsu M, et al. 2022. Sci Rep. 12:16656. PubMed
  85. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  86. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  87. Li Y, et al. 2020. Theranostics. 10:2897. PubMed
  88. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  89. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  90. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  91. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  92. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  93. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  94. Wang D, et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41:775. PubMed
  95. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  96. Song S, et al. 2021. Front Immunol. 12:705140. PubMed
  97. Tran NL, et al. 2022. Elife. 11:. PubMed
  98. Li H, et al. 2022. iScience. 25:104481. PubMed
  99. Jiang H, et al. 2022. Cell Death Dis. 13:183. PubMed
  100. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  101. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
  102. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  103. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  104. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  105. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  106. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  107. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
  108. Yuan C, et al. 2020. Braz J Med Biol Res. 53:e9488. PubMed
  109. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  110. Liu C, et al. 2022. Regen Ther. 21:192. PubMed
  111. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  112. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  113. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  114. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  115. Pan L, et al. 2022. Mol Immunol. 147:101. PubMed
  116. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  117. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  118. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  119. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  120. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  121. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  122. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  123. Ye Z, et al. 2023. Front Med (Lausanne). 9:1075465. PubMed
  124. Grenov A, et al. 2022. Cell Rep. 39:110778. PubMed
  125. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  126. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  127. Li T, et al. 2023. Adv Sci (Weinh). 10:e2206517. PubMed
  128. Sheng Y, et al. 2023. Cancers (Basel). 15:. PubMed
  129. Solier S, et al. 2023. Nature. 617:386. PubMed
  130. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  131. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  132. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  133. Kitagawa S, et al. 2022. NPJ Vaccines. 7:115. PubMed
  134. El-Hindi K, et al. 2022. Int J Mol Sci. 23:. PubMed
  135. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  136. Moreau J, et al. 2015. Blood. 126: 1184-1192. PubMed
  137. Lauterbach MA, et al. 2020. Immunity. 51(6):997-1011.e7.. PubMed
  138. Zhang Y, et al. 2018. Sci Rep. 8:5994. PubMed
  139. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  140. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  141. Saito S, et al. 2020. Nutrients. 12:. PubMed
  142. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  143. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  144. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  145. Xie Y, et al. 2020. Journal of Neurochemistry. 152(3):368-380.. PubMed
  146. Song M, et al. 2021. J Immunol Res. 6696606:2021. PubMed
  147. Chen F, et al. 2022. Evid Based Complement Alternat Med. 2022:1240242. PubMed
  148. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  149. Wu Q, et al. 2022. Cell Mol Life Sci. 79:137. PubMed
  150. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  151. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  152. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  153. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  154. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  155. Wang S, et al. 2018. Biomaterials. 187:28:00. PubMed
  156. Škrnjug I, et al. 2014. PLoS One. 9:110150. PubMed
  157. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  158. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  159. Jin R, et al. 2020. Mol Cancer Ther. . PubMed
  160. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  161. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  162. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  163. Varol D et al. 2017. Immunity. 46(6):1030-1044 . PubMed
  164. Bell CC, et al. 2019. Nat Commun. 10:2723. PubMed
  165. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  166. Reddi RN, et al. 2021. J Am Chem Soc. 143:4979. PubMed
  167. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  168. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  169. Jiang W, et al. 2021. J Cell Physiol. 236:7711. PubMed
  170. Wang Y, et al. 2022. Cell Death Dis. 13:748. PubMed
  171. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  172. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  173. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  174. Kramer K, et al. 2017. ACS Omega. 0.240972222. PubMed
  175. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  176. Venter C, et al. 2021. Physiol Rep. 9:e14704. PubMed
  177. Fan Q, et al. 2021. Bioact Mater. 6:4014. PubMed
  178. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  179. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  180. Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed
  181. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  182. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  183. Guo D, et al. 2022. Bone Res. 10:45. PubMed
  184. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  185. Shih F, et al. 2006. J Immunol. 176:3438. PubMed
  186. Gupta P, et al. 2019. Neoplasia. 0.976388889. PubMed
  187. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  188. Grabinger T, et al. 2019. Front Microbiol. 10:1385. PubMed
  189. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  190. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  191. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  192. Tomimatsu M, et al. 2022. Sci Rep. 12:16656. PubMed
  193. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  194. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  195. Li Y, et al. 2020. Theranostics. 10:2897. PubMed
  196. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  197. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  198. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  199. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  200. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  201. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  202. Wang D, et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41:775. PubMed
  203. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  204. Song S, et al. 2021. Front Immunol. 12:705140. PubMed
  205. Tran NL, et al. 2022. Elife. 11:. PubMed
  206. Li H, et al. 2022. iScience. 25:104481. PubMed
  207. Jiang H, et al. 2022. Cell Death Dis. 13:183. PubMed
  208. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  209. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
  210. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  211. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  212. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  213. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  214. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  215. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
  216. Yuan C, et al. 2020. Braz J Med Biol Res. 53:e9488. PubMed
RRID
AB_313151 (BioLegend Cat. No. 105008)
AB_313150 (BioLegend Cat. No. 105007)

Antigen Details

Structure
Ig superfamily, 80 kD
Distribution

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

Function
T cell costimulation, Ig class-switching, NK cell cytotoxicity
Ligand/Receptor
CD28, CD152 (CTLA-4)
Cell Type
Astrocytes, B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.

Gene ID
12524 View all products for this Gene ID
UniProt
View information about CD86 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
GL-1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-2, B70, Ly-58
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
GL-1
LPS (3-day) stimulated BALB/c mouse splenocytes stained with GL-1 PE
  • GL-1
    LPS (3-day) stimulated BALB/c mouse splenocytes stained with GL-1 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
105008 200 µg NOK2418
Check Availability


Need larger quantities of this item?
Request Bulk Quote
105007 50 µg NOK908
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
LPS-activated CBA/Ca mouse splenic B cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of acetone-fixed frozen sections2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105051-105056).

Application References
  1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
  2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
  5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
  6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
  11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed
Product Citations
  1. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  2. Liu C, et al. 2022. Regen Ther. 21:192. PubMed
  3. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  4. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  5. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  6. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  7. Pan L, et al. 2022. Mol Immunol. 147:101. PubMed
  8. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  9. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  10. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  11. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  12. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  13. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  14. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  15. Ye Z, et al. 2023. Front Med (Lausanne). 9:1075465. PubMed
  16. Grenov A, et al. 2022. Cell Rep. 39:110778. PubMed
  17. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  18. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  19. Li T, et al. 2023. Adv Sci (Weinh). 10:e2206517. PubMed
  20. Sheng Y, et al. 2023. Cancers (Basel). 15:. PubMed
  21. Solier S, et al. 2023. Nature. 617:386. PubMed
  22. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  23. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  24. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  25. Kitagawa S, et al. 2022. NPJ Vaccines. 7:115. PubMed
  26. El-Hindi K, et al. 2022. Int J Mol Sci. 23:. PubMed
  27. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  28. Moreau J, et al. 2015. Blood. 126: 1184-1192. PubMed
  29. Lauterbach MA, et al. 2020. Immunity. 51(6):997-1011.e7.. PubMed
  30. Zhang Y, et al. 2018. Sci Rep. 8:5994. PubMed
  31. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  32. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  33. Saito S, et al. 2020. Nutrients. 12:. PubMed
  34. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  35. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  36. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  37. Xie Y, et al. 2020. Journal of Neurochemistry. 152(3):368-380.. PubMed
  38. Song M, et al. 2021. J Immunol Res. 6696606:2021. PubMed
  39. Chen F, et al. 2022. Evid Based Complement Alternat Med. 2022:1240242. PubMed
  40. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  41. Wu Q, et al. 2022. Cell Mol Life Sci. 79:137. PubMed
  42. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  43. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  44. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  45. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  46. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  47. Wang S, et al. 2018. Biomaterials. 187:28:00. PubMed
  48. Škrnjug I, et al. 2014. PLoS One. 9:110150. PubMed
  49. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  50. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  51. Jin R, et al. 2020. Mol Cancer Ther. . PubMed
  52. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  53. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  54. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  55. Varol D et al. 2017. Immunity. 46(6):1030-1044 . PubMed
  56. Bell CC, et al. 2019. Nat Commun. 10:2723. PubMed
  57. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  58. Reddi RN, et al. 2021. J Am Chem Soc. 143:4979. PubMed
  59. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  60. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  61. Jiang W, et al. 2021. J Cell Physiol. 236:7711. PubMed
  62. Wang Y, et al. 2022. Cell Death Dis. 13:748. PubMed
  63. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  64. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  65. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  66. Kramer K, et al. 2017. ACS Omega. 0.240972222. PubMed
  67. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  68. Venter C, et al. 2021. Physiol Rep. 9:e14704. PubMed
  69. Fan Q, et al. 2021. Bioact Mater. 6:4014. PubMed
  70. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  71. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  72. Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed
  73. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  74. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  75. Guo D, et al. 2022. Bone Res. 10:45. PubMed
  76. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  77. Shih F, et al. 2006. J Immunol. 176:3438. PubMed
  78. Gupta P, et al. 2019. Neoplasia. 0.976388889. PubMed
  79. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  80. Grabinger T, et al. 2019. Front Microbiol. 10:1385. PubMed
  81. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  82. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  83. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  84. Tomimatsu M, et al. 2022. Sci Rep. 12:16656. PubMed
  85. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  86. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  87. Li Y, et al. 2020. Theranostics. 10:2897. PubMed
  88. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  89. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  90. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  91. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  92. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  93. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  94. Wang D, et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41:775. PubMed
  95. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  96. Song S, et al. 2021. Front Immunol. 12:705140. PubMed
  97. Tran NL, et al. 2022. Elife. 11:. PubMed
  98. Li H, et al. 2022. iScience. 25:104481. PubMed
  99. Jiang H, et al. 2022. Cell Death Dis. 13:183. PubMed
  100. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  101. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
  102. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  103. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  104. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  105. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  106. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  107. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
  108. Yuan C, et al. 2020. Braz J Med Biol Res. 53:e9488. PubMed
  109. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  110. Liu C, et al. 2022. Regen Ther. 21:192. PubMed
  111. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  112. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  113. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  114. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  115. Pan L, et al. 2022. Mol Immunol. 147:101. PubMed
  116. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  117. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  118. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  119. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  120. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  121. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  122. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  123. Ye Z, et al. 2023. Front Med (Lausanne). 9:1075465. PubMed
  124. Grenov A, et al. 2022. Cell Rep. 39:110778. PubMed
  125. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  126. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  127. Li T, et al. 2023. Adv Sci (Weinh). 10:e2206517. PubMed
  128. Sheng Y, et al. 2023. Cancers (Basel). 15:. PubMed
  129. Solier S, et al. 2023. Nature. 617:386. PubMed
  130. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  131. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  132. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  133. Kitagawa S, et al. 2022. NPJ Vaccines. 7:115. PubMed
  134. El-Hindi K, et al. 2022. Int J Mol Sci. 23:. PubMed
  135. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  136. Moreau J, et al. 2015. Blood. 126: 1184-1192. PubMed
  137. Lauterbach MA, et al. 2020. Immunity. 51(6):997-1011.e7.. PubMed
  138. Zhang Y, et al. 2018. Sci Rep. 8:5994. PubMed
  139. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  140. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  141. Saito S, et al. 2020. Nutrients. 12:. PubMed
  142. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  143. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  144. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  145. Xie Y, et al. 2020. Journal of Neurochemistry. 152(3):368-380.. PubMed
  146. Song M, et al. 2021. J Immunol Res. 6696606:2021. PubMed
  147. Chen F, et al. 2022. Evid Based Complement Alternat Med. 2022:1240242. PubMed
  148. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  149. Wu Q, et al. 2022. Cell Mol Life Sci. 79:137. PubMed
  150. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  151. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  152. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  153. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  154. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  155. Wang S, et al. 2018. Biomaterials. 187:28:00. PubMed
  156. Škrnjug I, et al. 2014. PLoS One. 9:110150. PubMed
  157. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  158. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  159. Jin R, et al. 2020. Mol Cancer Ther. . PubMed
  160. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  161. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  162. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  163. Varol D et al. 2017. Immunity. 46(6):1030-1044 . PubMed
  164. Bell CC, et al. 2019. Nat Commun. 10:2723. PubMed
  165. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  166. Reddi RN, et al. 2021. J Am Chem Soc. 143:4979. PubMed
  167. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  168. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  169. Jiang W, et al. 2021. J Cell Physiol. 236:7711. PubMed
  170. Wang Y, et al. 2022. Cell Death Dis. 13:748. PubMed
  171. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  172. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  173. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  174. Kramer K, et al. 2017. ACS Omega. 0.240972222. PubMed
  175. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  176. Venter C, et al. 2021. Physiol Rep. 9:e14704. PubMed
  177. Fan Q, et al. 2021. Bioact Mater. 6:4014. PubMed
  178. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  179. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  180. Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed
  181. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  182. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  183. Guo D, et al. 2022. Bone Res. 10:45. PubMed
  184. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  185. Shih F, et al. 2006. J Immunol. 176:3438. PubMed
  186. Gupta P, et al. 2019. Neoplasia. 0.976388889. PubMed
  187. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  188. Grabinger T, et al. 2019. Front Microbiol. 10:1385. PubMed
  189. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  190. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  191. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  192. Tomimatsu M, et al. 2022. Sci Rep. 12:16656. PubMed
  193. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  194. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  195. Li Y, et al. 2020. Theranostics. 10:2897. PubMed
  196. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  197. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  198. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  199. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  200. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  201. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  202. Wang D, et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41:775. PubMed
  203. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  204. Song S, et al. 2021. Front Immunol. 12:705140. PubMed
  205. Tran NL, et al. 2022. Elife. 11:. PubMed
  206. Li H, et al. 2022. iScience. 25:104481. PubMed
  207. Jiang H, et al. 2022. Cell Death Dis. 13:183. PubMed
  208. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  209. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
  210. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  211. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  212. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  213. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  214. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  215. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
  216. Yuan C, et al. 2020. Braz J Med Biol Res. 53:e9488. PubMed
RRID
AB_313151 (BioLegend Cat. No. 105008)
AB_313150 (BioLegend Cat. No. 105007)

Antigen Details

Structure
Ig superfamily, 80 kD
Distribution

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

Function
T cell costimulation, Ig class-switching, NK cell cytotoxicity
Ligand/Receptor
CD28, CD152 (CTLA-4)
Cell Type
Astrocytes, B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.

Gene ID
12524 View all products for this Gene ID
UniProt
View information about CD86 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account